Cardiotoxicity Induced by Trastuzumab Therapy in HER2-positive Breast Cancer
the Cancer Therapy Advisor take:
Trastuzumab therapy appears to be a safe treatment option for patients with asymptomatic treatment-induced cardiotoxicity (left ventricular ejection fraction [LVEF] of ≥50%), according to an article published online in the journal The Oncologist.
The authors studied patients with HER2-positive breast cancer who were administered adjuvant trastuzumab between 2005 and 2010.
An absolute decrease in LVEF of greater than or equal to 10% to below 55% or an absolute decline of greater than or equal to 16% was the definition of treatment-induced cardiotoxicity for this study.
Results showed 92 out of 573 (16%) patients developed trastuzumab treatment-induced cardiotoxicity. Thirty-one of these 92 patients were able to continue receiving trastuzumab without interruption—all patients were asymptomatic at cardiotoxicity diagnosis (LVEF of ≥50%) with a median LVEF of 53% (range, 50%–63%), and no patients were reported to have developed heart failure during follow-up.
Furthermore, treatment-induced cardiotoxicity related risk factors included age (P =0.011), anthracycline chemotherapy (P =0.002), and lower pretrastuzumab LVEF (P<0.001).
Trastuzumab therapy appears to be a safe treatment option for patients with asymptomatic treatment-induced cardiotoxicity.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Q&A With Mark B. Gerstein, PhD, on Diagnostic Genomic vs Exomic Sequencing
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
- Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma
- Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed